natgillin/translations-raw huggingface dataset:
Clinically relevant toxicity that was reported in ≥ 1 % and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Među klinički značajne oblike toksičnosti prema CTC kriterijima, prijavljene u ≥ 1% i ≤ 5% bolesnika randomiziranih u skupinu koja je primala pemetreksed, ubrajaju se: infekcija bez neutropenije, neutropenijska vrućica, alergijska reakcija/preosjetljivost, povišene vrijednosti kreatinina, motorička neuropatija, senzorna neuropatija, multiformni eritem i bol u abdomenu.
Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5 % of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Među klinički značajne oblike toksičnosti prema CTC kriterijima, prijavljene u ≥ 1% i ≤ 5% bolesnika randomiziranih da primaju cisplatin i pemetreksed ubrajaju se: povišene vrijednosti AST-a, povišene vrijednosti ALT-a, infekcija, neutropenijska vrućica, zatajenje bubrega, vrućica, dehidracija, konjunktivitis i smanjen klirens kreatinina.
Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Među klinički značajne oblike toksičnosti prema CTC kriterijima, prijavljene u ≥ 1% i ≤ 5% bolesnika randomiziranih u skupinu koja je primala cisplatin i pemetreksed ubrajaju se: povišene vrijednosti AST- a, povišene vrijednosti ALT-a, infekcija, neutropenijska vrućica, zatajenje bubrega, pireksija, dehidracija, konjuktivitis i smanjen klirens kreatinina.
Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5% of the patients that were randomly assigned to receive cisplatin and pemetrexed include: AST increase, ALT increase, infection, febrile neutropenia, renal failure, pyrexia, dehydration, conjunctivitis, and creatinine clearance decrease.
Među klinički značajne oblike toksičnosti prema CTC kriterijima, prijavljene u ≥ 1% i ≤ 5% bolesnika randomiziranih u skupinu koja je primala cisplatin i pemetreksed ubrajaju se: povišene vrijednosti AST-a, povišene vrijednosti ALT-a, infekcija, neutropenijska vrućica, zatajenje bubrega, pireksija, dehidracija, konjuktivitis i smanjen klirens kreatinina.
Clinically significant active bleeding.
Klinički značajno aktivno krvarenje.
Clinically significant adverse reactions observed in clinical trials included hypotension and ventricular arrhythmia. (see sections 4.4 Hypotension, Congestive Heart Failure).
Klinički značajne nuspojave opažene u kliničkim ispitivanjima bile su hipotenzija i ventrikularna aritmija. (Vidjeti dijelove 4.4 Hipotenzija, Kongestivno zatajenje srca).
Clinically significant bladder outflow obstruction at risk of urinary retention (e.g. clinically significant prostate enlargement due to benign prostatic hyperplasia, see section 4.3)
klinički značajnom opstrukcijom izlaza mokraćnog mjehura i rizikom od retencije mokraće (npr., klinički značajno povećanje prostate zbog benigne hiperplazije prostate, vidjeti dio 4.3)
Clinically significant disorders of the gastrointestinal, cardiovascular, respiratory, endocrine (including diabetes, Cushing’s disease, Addison’s disease, Peutz-Jeghers syndrome), neurological (including seizures) and haematological (especially anaemia) systems have not been evaluated.
Klinički značajni poremećaji gastrointestinalnog, kardiovaskularnog, respiratornog, endokrinog sustava (uključujući dijabetes, Cushingovu bolest, Addisonovu bolest, Peutz-Jeghersov sindrom), neurološki (uključujući napadaje) i hematološki poremećaji (posebice anemija) nisu ocijenjeni.
Clinically significant gender-related differences in dalbavancin pharmacokinetics have not been observed in healthy subjects or in patients with infections.
Nisu uočene klinički značajne razlike povezane sa spolom u farmakokinetici dalbavancina u zdravih ispitanika ili bolesnika s infekcijom.
Clinically significant hepatic
do klinički značajnog
clinically significant hepatic impairment concomitant or planned administration of another parenteral glycoprotein (GP) IIb/IIIa inhibitor
klinički značajnim oštećenjem jetre kojima se istodobno daje ili se planira davati drugi parenteralni inhibitor glikoproteina (GP) IIb/IIIa
Clinically significant hypercalcaemia has been reported in XGEVA-treated patients with growing skeletons weeks to months following treatment discontinuation.
Klinički značajna hiperkalcijemija prijavljena je kod bolesnika sa skeletom u razdoblju rasta liječenih lijekom XGEVA tjednima do mjesecima nakon prekida liječenja.
Clinically significant inhibitory or inductive effects of azacitidine on cytochrome P450 enzymes are unlikely (see section 5.2).
Klinički značajni inhibicijski ili indukcijski učinci azacitidina na enzime citokroma P450 nisu vjerojatni (vidjeti dio 5.2).
Clinically significant interaction unlikely.
Klinički značajna interakcija malona.
Clinically significant interactions are not expected as simeprevir and emtricitabine are eliminated via different pathways.
očekuju se klinički značajne interakcije jer se simeprevir i emtricitabin eliminiraju različitim putevima.
Clinically significant interactions are not expected since vigabatrin and gabapentin are exclusively eliminated unchanged in the urine and are unlikely to compete for the same metabolic enzymes and elimination pathways as efavirenz.
očekuju se klinički značajne interakcije jer se vigabatrin i gabapentin eliminiraju nepromijenjeni isključivo u mokraći i nije vjerojatno da bi se natjecali za metabolitičke enzime i puteve eliminacije efavirenza.
Clinically significant methaemoglobinaemia should be treated with a slow intravenous injection of methylthioninium chloride.
Klinički značajna methemoglobinemija treba se liječiti polaganim intravenskim injiciranjem metiltioninij klorida.
Clinically the following substances have been shown to decrease tacrolimus blood levels:
Klinički se pokazalo da sljedeće tvari mogu smanjiti koncentraciju takrolimusa u krvi:
Clinically the following substances have been shown to decrease tacrolimus blood levels:
Klinički se pokazalo da sljedeće tvari smanjuju koncentraciju takrolimusa u krvi:
Clinically the following substances have been shown to increase tacrolimus blood levels:
Klinički se pokazalo da sljedeće tvari povećavaju koncentracije takrolimusa u krvi:
Clinically the following substances have been shown to increase tacrolimus blood levels:
Klinički se pokazalo da sljedeće tvari povećavaju koncentraciju takrolimusa u krvi:
Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate.
klinički tipičnih, nehiperkeratotičnih, nehipertrofičnih aktiničnih keratoza na licu ili tjemenu u odraslih imunokompetentnih bolesnika kada veličina ili broj lezija ograničuje djelotvornost i/ili primjenjivost krioterapije, a druge topikalne metode liječenja su kontraindicirane ili manje pogodne.
Clinically validated phenotypic interpretation systems may be used in association with the genotypic data to estimate the activity of amprenavir / ritonavir or fosamprenavir / ritonavir in patients with PI- resistant isolates.
Za procjenu aktivnosti amprenavira/ritonavira ili fosamprenavira/ritonavira kod bolesnika s izolatima otpornim na IP mogu se koristiti klinički validirani sistemi za fenotipsku interpretaciju.
Clinically, activity in tumours harbouring the T790M mutation in exon 20 has also been shown.
Klinički je također pokazana aktivnost u tumora s T790M mutacijom u egzonu 20.
Clinically, an increased metabolism of oestrogens may lead to decreased effect and changes in the uterine bleeding profile.
Klinički, pojačani metabolizam estrogena može dovesti do smanjenog učinka i promjena u profilu materničnog krvarenja.
Clinically, the following substances have been shown to increase tacrolimus blood levels:
Klinički je pokazano da sljedeće tvari povećavaju razine takrolimusa u krvi:
Clinigen Healthcare Ltd Pitcairn House,
Clinigen Healthcare Ltd
Clip Rubber Seal Plunger Pen Body
Klip Tijelo brizgalice
CLL and FL are types of cancer that affect white blood cells called “B-lymphocytes”.
KLL i FL su vrste raka koje zahvaćaju bijele krvne stanice koje se zovu B-limfociti.
CLL is a cancer of B-lymphocytes, a type of white blood cells.
KLL je rak B-limfocita, vrste bijelih krvnih stanica.
CLL only – Cycle 1
Samo KLL – 1. ciklus
CLL/WM dose modification after recovery
Prilagodba doze nakon oporavka za kroničnu limfocitnu leukemiju/Waldenströmovu makroglobulinemiju
CLlung was found to be significantly reduced (51%) in females compared to males (all subjects).
Uočeno je da je CLpluća bio značajno smanjen (51%) u žena u usporedbi s muškarcima (svi ispitanici).
Clofarabine AUC0-24 hours by baseline estimated creatinine clearance in patients aged between 2 to 19 years old with relapsed or refractory ALL or AML (n = 11 / n = 12) following administration of multiple doses of clofarabine by intravenous infusion
Klofarabin AUC0-24 sata prema početnoj vrijednosti klirensa kreatinina u bolesnika u dobi između 2 i 19 godina s relapsnom ili refraktorom ALL ili AML (n = 11 / n = 12) nakon primjene višekratnih doza klofarabina intravenskom infuzijom
Clofarabine has high affinity for one of the activating phosphorylating enzymes, deoxycytidine kinase, which exceeds that of the natural substrate, deoxycytidine.
Klofarabin ima visok afinitet prema jednom od aktivirajućih fosforilirajućih enzima, deoksicitidin kinazi, koji nadilazi afinitet prirodnog supstrata, deoksicitidina.
Clofarabine is an ‘analogue’ of adenine, which is part of the fundamental genetic material of cells (DNA and RNA).
Klofarabin je analogan adeninu koji je dio osnovnog genetskog materijala stanica (DNK i RNK).
Clofarabine is not detectably metabolised by the cytochrome P450 (CYP) enzyme system.
Nije zabilježen primjetan metabolizam klofarabina posredstvom enzimskog sustava citokroma P450 (CYP).
Clofarabine must first diffuse or be transported into target cells where it is sequentially phosphorylated to the mono- and bi-phosphate by intracellular kinases, and then finally to the active conjugate, clofarabine 5’-triphosphate.
Klofarabin prvo mora difundirati ili biti prenesen u ciljne stanice gdje se djelovanjem unutarstaničnih kinaza sekvencijalno fosforilira u mono- i difosfat, a potom i u aktivni konjugat, klofarabin 5'-trifosfat.
clogging of a very small blood vessel(s) in the kidney,
začepljenje vrlo malih krvnih žila u bubregu
Clomicalm 20 mg tablets for dogs Clomipramine hydrochloride
Clomicalm 20 mg tablete za pse Klomipramin hidroklorid
Clomicalm 5 mg tablets for dogs Clomipramine hydrochloride
Clomicalm 5 mg tablete za pse Klomipramin hidroklorid
Clomicalm 80 mg tablets for dogs Clomipramine hydrochloride
Clomicalm 80 mg tablete za pse Klomipramin hidroklorid
Clomicalm is administered twice daily at a dose of 1-2 mg/kg clomipramine to give a total daily dose of 2-4 mg/kg according to the following table:
Clomicalm treba primjenjivati u dozi od 1 - 2 mg/kg klomipramina dva puta dnevno, kako bi se dala ukupna dnevna doza od 2 - 4 mg/kg u skladu sa sljedećom tablicom:
Clomicalm is may be given orally with or without food.
Clomicalm se može dati peroralno s hranom ili bez nje.
Clomicalm may increase the effects of the anti-arrhythmic drug quinidine, anticholinergic agents (e.g. atropine), other CNS active drugs (e.g. barbiturates, benzodiazepines, general anaesthetics, neuroleptics), sympathomimetics (e.g. adrenaline) and coumarine derivatives.
Clomicalm može potencirati učinke antiaritmičkog lijeka kinidina, antikolinergičnih lijekova (primjerice atropina), drugih lijekova koji djeluju na SŽS (primjerice barbiturata, benzodiazepina, općih anestetika, neuroleptika), simpatomimetika (primjerice adrenalina) i derivata kumarina.
Clomicalm should only be given in combination with behavioural therapy.
VMP Clomicalm smije se primjenjivati samo u kombinaciji s bihevioralnom terapijom.
Clomipramine has a broad-spectrum of action in blocking the neuronal reuptake of both serotonin (5- HT) and noradrenaline.
Clomipramine ima široki spektar djelovanje u blokadi ponovne pohrane serotonina (5-HT) i noradrenalina u neurone.
Clomipramine hydrochloride
Klomipramin hidroklorid
Clomipramine hydrochloride 20 mg (equivalent to 17.9 mg Clomipramine)
Klomipramin hidroklorid 20 mg (odgovara 17,9 mg klomipramina)
Clomipramine hydrochloride 5 mg (equivalent to 4.5 mg Clomipramine)
Klomipramin hidroklorid 5 mg (odgovara 4,5 mg klomipramina)
Clomipramine hydrochloride 80 mg (equivalent to 71.7 mg Clomipramine)
Klomipramin hidroklorid 80 mg (odgovara 71,7 mg klomipramina)
Clomipramine hydrochloride mg (equivalent to 71.7 mg Clomipramine)
Klomipramin hidroklorid 80 mg (odgovara 71,7 mg klomipramina)
clomipramine)
(sakvinavir/ritonavir)
Clonazepam
klonazepam
clonidine (used to treat high blood pressure) may extend the effects of this medicine. anti-retrovirals (used to treat HIV) such as ritonavir, nelfinavir, indinavir may increase the effects of this medicine.
klonidin (koristi se za liječenje visokog krvnog tlaka) može produljiti učinke ovog lijeka. antiretrovirotici (koji se koriste za liječenje HIV-a) poput ritonavira, nelfinavira i indinavira mogu povećati učinke ovog lijeka.
clonidine (used to treat high blood pressure) may extend the effects of this medicine. anti-retrovirals (used to treat HIV) such as ritonavir, nelfinavir, indinavir may increase the effects of this medicine.
klonidin (koristi se za liječenje visokog krvnog tlaka) može produljiti učinke ovog lijeka. antiretrovirotici (koriste se za liječenje HIV-a) poput ritonavira, nelfinavira i indinavira mogu povećati učinke ovog lijeka.
clonidine (used to treat high blood pressure), lithium salts (used to treat psychiatric disorders).
klonidin (koristi se za liječenje visokog krvnog tlaka) soli litija (koriste se za liječenje psihijatrijskih poremećaja)
clonidine (used to treat high blood pressure), lithium salts (used to treat psychiatric disorders).
klonidin (koristi se za liječenje visokog krvnog tlaka), soli litija (koriste se za liječenje psihijatrijskih poremećaja).
clonidine (used to treat high blood pressure), lithium salts (usedto treat psychiatric disorders).
klonidin (koristi se za liječenje visokog krvnog tlaka), soli litija (koriste se za liječenje psihijatrijskih poremećaja).
Clonidine, guanfacine, used to treat hypertension.
klonidinom, gvanfacinom - koriste se za liječenje povišenog krvnog tlaka.
Clonus Dysgeusia Hypoaesthesia Hypogeusia
Klonus Disgeuzija Hipoestezija Hipogeuzija
Clopidogre ratiopharm
EU/1/14/975/008
Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.
Klopidogrel (početna doza od 300 mg, potom doza održavanja od 75 mg) nije pokazao farmakokinetičku interakciju s rivaroksabanom (15 mg) , ali je uočeno značajno produženje vremena krvarenja u podskupini bolesnika, koje nije bilo u korelaciji s agregacijom trombocita, s razinama P- selektina ili GPIIb/IIIa-receptora.
Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.
Klopidogrel (početna doza od 300 mg, potom doza održavanja od 75 mg) nije pokazao farmakokinetičku interakciju s rivaroksabanom (15 mg), ali je uočeno značajno produženje vremena krvarenja u podskupini bolesnika, koje nije bilo u korelaciji s agregacijom trombocita, s razinama P- selektina ili GPIIb/IIIa-receptora.
Clopidogrel (300 mg loading dose followed by 75 mg maintenance dose) did not show a pharmacokinetic interaction with rivaroxaban (15 mg) but a relevant increase in bleeding time was observed in a subset of patients which was not correlated to platelet aggregation, P-selectin or GPIIb/IIIa receptor levels.
Klopidogrel (početna doza od 300 mg, potom doza održavanja od 75 mg) nije pokazao farmakokinetičku interakciju s rivaroksabanom (15mg) , ali je uočeno značajno produženje vremena krvarenja u podskupini bolesnika, koje nije bilo u korelaciji s agregacijom trombocita, s razinama P- selektina ili GPIIb/IIIa-receptora.
Clopidogrel (N=12542)
Klopidogrel (N= 12 542)
Clopidogrel (N=5527)
Klopidogrel (N= 5527)
Clopidogrel (prevents blood clots)
klopidogrel (sprječava zgrušavanje krvi)
Clopidogrel (prevents blood clots)
Klopidogrel (sprječava zgrušavanje krvi).
Clopidogrel (prevents blood clots).
klopidogrel (sprječava zgrušavanje krvi)
Clopidogrel (prevents blood clots).
Klopidogrel (sprječava zgrušavanje krvi).
Clopidogrel / acetylsalicylic acid Teva
EU/1/14/942/005
Clopidogrel Acino 75 mg
Klopidogrel Acino 75 mg
Clopidogrel Acino 75 mg film-coated tablets
Klopidogrel Acino 75 mg filmom obložene tablete
Clopidogrel Acino can be started between a few days and 35 days after the attack; patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
Terapija lijekom Clopidogrel Acino može se započeti u razdoblju od nekoliko dana do 35 dana nakon infarkta; su nedavno pretrpjeli ishemijski moždani udar (moždani udar uzrokovan nedovoljnom opskrbom krvi u nekom dijelu mozga).
Clopidogrel Acino contains hydrogenated castor oil
Klopidogrel Acino sadrži hidrogenirano ricinusovo ulje
Clopidogrel Acino contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Klopidogrel Acino sadrži hidrogenirano ricinusovo ulje koje može uzrokovati probavne tegobe i proljev.
Clopidogrel Acino is a medicine that contains the active substance clopidogrel.
Clopidogrel Acino je lijek koji sadrži djelatnu tvar Clopidogrel.
Clopidogrel Acino is a ‘generic medicine’.
Clopidogrel Acino je „generički lijek”.
Clopidogrel Acino is unlikely to affect your ability to drive or to use machines.
Klopidogrel Acino ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
Clopidogrel Acino may be taken with or without food.
Klopidogrel Acino se može uzimati s obrokom ili bez obroka.
Clopidogrel Acino with food and drink
Klopidogrel Acino s hranom i pićem
Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.
Aktivni tiolni metabolit, koji je izoliran in vitro, brzo se i ireverzibilno veže na receptore na trombocitima i time inhibira agregaciju trombocita.
Clopidogrel and ASA: From the data collected in the phase III study RE-LY (see section 5.1) it was observed that the concomitant use of antiplatelets, ASA or clopidogrel approximately doubles major bleeding rates with both dabigatran etexilate and warfarin (see section 4.4).
Klopidogrel i acetilsalicilna kiselina: Iz podataka prikupljenih u studiji RE-LY faze III (vidjeti dio 5.1), primijećeno je da istovremena primjena antitrombotika, acetilasalicilne kiseline ili klopidogrela približno udvostručuje stopu velikih krvarenja i uz dabigatraneteksilat i varfarin (vidjeti dio 4.4).
Clopidogrel Apotex 75 mg film-coated tablets
Clopidogrel Apotex 75 mg filmom obložene tablete
Clopidogrel Apotex contains lactose.
Clopidogrel Apotex sadrži laktozu.
Clopidogrel Apotex contains lactose:
Clopidogrel Apotex sadrži laktozu:
Clopidogrel Apotex is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Clopidogrel Apotex uzimaju odrasli za sprječavanje stvaranja krvnih ugrušaka (tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
Clopidogrel Apotex is unlikely to affect your ability to drive or to use machines.
Clopidogrel Apotex ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
Clopidogrel Apotex may be taken with or without food.
Clopidogrel Apotex se može uzimati s obrokom ili bez obroka.
Clopidogrel Apotex with food and drink
Clopidogrel Apotex s hranom i pićem
Clopidogrel BGR 75 mg film-coated tablets Clopidogrel
Clopidogrel BGR 75 mg filmom obložene tablete
Clopidogrel BGR 75 mg film-coated tablets Clopidogrel
Clopidogrel BGR 75 mg filmom obložene tablete klopidogrel
Clopidogrel BGR can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel BGR može se davati sljedećim skupinama bolesnika: bolesnicima koji su nedavno doživjeli infarkt miokarda (srčani udar).
Clopidogrel BGR can be started between a few days and 35 days after the attack; patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
Terapija lijekom Clopidogrel BGR može započeti između nekoliko dana i 35 dana nakon srčanog udara; bolesnicima koji su nedavno doživjeli ishemijski udar (moždani udar uzrokovan zatajenjem dotoka krvi u dio mozga).
Clopidogrel BGR can be started between seven days and six months after the stroke; patients with peripheral arterial disease (problems with blood flow in the arteries);
Terapija lijekom Clopidogrel BGR može započeti između sedam dana i šest mjeseci nakon moždanog udara; bolesnicima s perifernom bolešću arterija (problemima s protokom krvi u arterijama); Ovaj se lijek izdaje samo na liječnički recept.
Clopidogrel BGR contains hydrogenated castor oil
Clopidogrel BGR sadrži hidrogenirano ricinusovo ulje
Clopidogrel BGR contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Clopidogrel BGR sadrži hidrogenirano ricinusovo ulje koje može uzrokovati probavne tegobe i proljev.
Clopidogrel BGR is a ‘generic medicine’.
Clopidogrel BGR je „generički lijek”.
Clopidogrel BGR is unlikely to affect your ability to drive or to use machines.
Clopidogrel BGR ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
Clopidogrel dura 75 mg film-coated tablets
Clopidogrel dura 75 mg filmom obložene tablete
Clopidogrel dura contains hydrogenated castor oil
Clopidogrel dura hidrogenirano ricinusovo ulju
Clopidogrel HCS can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel HCS može se primjenjivati u sljedećih skupina bolesnika: bolesnika koji su nedavno pretrpjeli infarkt miokarda (srčani udar).
Clopidogrel HCS can be started between a few days and 35 days after the attack; patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
Terapija lijekom Clopidogrel HCS može se započeti od nekoliko dana do 35 dana nakon infarkta; bolesnika koji su nedavno pretrpjeli ishemijski moždani udar (udar uzrokovan neprimjerenom isporukom krvi u dio mozga).
Clopidogrel HCS can be used in patients who are having a heart attack with ‘ST segment elevation’ (an abnormal reading on the ECG or electrocardiogram) when the doctor thinks that they would benefit from the treatment.
Clopidogrel HCS može se primjenjivati u bolesnika koji imaju srčani udar s „povišenjem segmenta ST” (abnormalni rezultat EKG-a ili elektrokardiograma) u slučaju kada liječnik smatra da bi imali koristi od ove terapije.
Clopidogrel HCS is a ‘generic medicine’.
Clopidogrel HCS je „generički lijek”.
Clopidogrel HCS is unlikely to affect your ability to drive or to use machines.
Klopidogrel HCS ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.